11:29 AM EDT, 10/19/2026 (MT Newswires) -- ALK-Abelló's (ALK-B.CO) phase 3 trial of its Acarizax drug showed positive results in Chinese patients aged 12 to 65 with house dust mite allergic rhinitis or rhinoconjunctivitis, with or without asthma. The Danish pharmaceutical company said Monday the trial met its primary goal, with the treatment reducing allergy symptoms by 19.1% compared with placebo. The tablet was also deemed safe and well-tolerated. ALK-Abelló and biopharmaceutical partner GenSci plan to seek Chinese regulatory approval for Acarizax, with a filing expected in the first half of 2027.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.